Eli Lilly and Company $LLY Shares Acquired by Impax Asset Management Group plc

Impax Asset Management Group plc boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 12.7% in the second quarter, HoldingsChannel.com reports. The firm owned 69,241 shares of the company’s stock after acquiring an additional 7,803 shares during the period. Impax Asset Management Group plc’s holdings in Eli Lilly and Company were worth $53,975,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of the business. PNC Financial Services Group Inc. increased its position in Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock worth $83,669,349,000 after buying an additional 50,002,551 shares during the period. Nuveen LLC acquired a new position in shares of Eli Lilly and Company during the first quarter valued at $4,613,912,000. Vanguard Group Inc. grew its position in shares of Eli Lilly and Company by 6.7% during the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock worth $65,432,218,000 after acquiring an additional 4,975,395 shares during the last quarter. Assenagon Asset Management S.A. grew its position in shares of Eli Lilly and Company by 106.8% during the second quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock worth $1,154,508,000 after acquiring an additional 765,010 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Eli Lilly and Company by 13.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock worth $4,808,443,000 after acquiring an additional 682,203 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on LLY shares. Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. Cantor Fitzgerald boosted their price target on Eli Lilly and Company from $925.00 to $985.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. UBS Group increased their price target on Eli Lilly and Company from $895.00 to $1,080.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Guggenheim reaffirmed a “buy” rating and issued a $948.00 price objective on shares of Eli Lilly and Company in a report on Thursday, October 16th. Finally, Leerink Partners upgraded shares of Eli Lilly and Company from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $886.00 to $1,104.00 in a research report on Monday. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $990.11.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $1,018.28 on Thursday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,022.42. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a market cap of $962.67 billion, a PE ratio of 66.55, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The company’s 50-day moving average price is $815.33 and its two-hundred day moving average price is $778.16.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same quarter last year, the firm posted $1.18 EPS. The business’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be given a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s payout ratio is 29.35%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.